USE OF CANNABINOIDS IN THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

摘要

Cannabidiol (CBD) for use in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) characterised in that the LGS patients are deemed to be treatment failure on one or more anti-epileptic drugs (AEDs). Preferably the one or more AEDs are selected from rufinamide, lamotrigine, topiramate and/or felbamate. Preferably the CBD is in the form of a highly purified extract of cannabis which comprises at least 98% (w/w) CBD, less than 0.15% tetrahydrocannabinol (THC) and up to 1% cannabidivarin (CBDV). The CBD may be present as a synthetic compound. Preferably the dose of CBD is below 50mg/kg/day but greater than 20mg/kg/day.